Abstract:Objective To evaluate the efficacy,safety and tolerance of continuous erythropoietin receptor activator (CERA) once every 2 weeks intravenous injection on anemia correction in dialysis patients compared to Epoetin-3 (EPO-β) administration.Methods An open-label,randomized,parallel,active-control and multi-center clinical trial was performed.All the hemodialysis or peritoneal dialysis patients with chronic renal anemia who had not been treated with erythropoiesis-stimulating agents (ESAs)for at least 8 weeks before entering the treatment phase were randomized (1∶1) to receive either CERA once every 2 weeks intravenous administration (CERA group,n=132) or intravenous EPO-β three times weekly (EPO group,n=133) for 24 weeks including 16-week correction period and 8-week efficacy evaluation period.At week 25,the patients who reached the target Hb (defined as Hb≥ 110 g/L and increase in Hb≥10 g/L from baseline without red blood cell transfusion during the 24 weeks after the first dose) were kept on CERA or EPO-β treatment regimen for the subsequent 28 weeks to evaluate the long-term safety and tolerability.The starting dose of CERA was 0.4 μg/kg.Two primary endpoints were (1) the Hb response rate during the first 24 weeks; and (2)the mean change in Hb between the baseline and the evaluation periods (week 17 to week 24).Results Totally 232 patients (87.5％) completed the first 24-week treatment and 198 patients (74.7％) completed the whole study treatment (52 weeks).The response rate in CERA group during the first 24 weeks was 87.12％[95％ CI(80.2％ to 92.3％)].Since the lower limit of the 95％CI was greater than 60％ (P ＜ 0.01),CERA once every 2 weeks intravenous administration was considered as effective in correction of renal anemia.The difference between CERA group and EPO group in mean change of Hb from evaluation periods to baseline in the per-protocol (PP) population was-4.7 g/L [95％CI (-7.38 g/L to-1.92 g/L)].Since the lower limit of 95％CI was greater than the pre-defined noninferiority margin-7.5 g/L (P=0.0205),CERA was considered as non-inferior to EPO in the maintenance of Hb after anemia correction.The Hb level remained stable during the subsequent 28-week extension period in both CERA and EPO groups.During the whole study period,the overall safety findings were similar in CERA and EPO groups,50.0％ and 54.6％ of patients experienced at least one adverse event (AE) respectively.The findings from AEs were in accordance with the characteristics of the studied population.Conclusions Intravenous CERA once every 2 weeks is safe and effective for correcting anemia in dialysis patients.Treatment with CERA once every 2 weeks is also non-inferior to 3 times weekly EPO in maintaining the Hb level after the correction.In general,long-term intravenous administration of CERA is well tolerated by dialysis patients with chronic renal anemia.

Preliminary excretion study of CERA in human urine and serums : which is the better matrix for detecting CERA abuse ?

[Determination Methods for Erythropoietin Receptor Activator in Human Urine].

Efficacy,safety and Tolerance of Continuous Erythropoietin Receptor Activator Intravenous Administration on Anemia Correction in Dialysis Patients with Chronic Renal Anemia

Separation and Detection of Erythropoietin by Ce and Ce-Ms

Trends in the Detection of Erythropoietin Receptor Agonists (ERAs) in Anti‐Doping: An Analysis of Recent Adverse Analytical Findings (AAFs)

[Determination of Beta-Estradiol, Bisphenol A, Diethylstilbestrol and Salbutamol in Human Urine by GC/MS].

[The Efficacy and Safety of Continuous Erythropoietin Receptor Activator in Dialytic Patients with Chronic Renal Anemia: an Open, Randomized, Controlled, Multi-Center Trial].

Assessing EPO stability in urine and comparing recombinant EPO detectability in matched urine, venous serum, and capillary serum following a controlled epoetin alfa administration

Recent Advance in the CE and CE-MS Detection of Recombinant Human Erythropoietin in Doping Control

A column-switching liquid chromatography-tandem mass spectrometry method for quantitation of 2-cyanoethylmercapturic acid and 2-hydroxyethylmercapturic acid in Chinese smokers.

Two-Dimensional Liquid Chromatography Purified GC/C/IRMS Doping Control Method: Analysis of Endogenous and Exogenous Sources in Urine Samples from Asian Subjects Administered a Low Dose of AICAR

Detecting EPO in Microvolumetric Capillary Serum Shipped at Ambient Temperature for Antidoping Testing

Dried blood spots for erythropoietin analysis: Detection of micro-doses, EPO c.577del variant and comparison with in-competition matching urine samples

High-throughput and Selective Solid-Phase Extraction of Urinary Catecholamines by Crown Ether-Modified Resin Composite Fiber.

Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacycline

Ephedrine Analysis in Real Urine Sample via Solvent Bar Microextraction Technique Coupled with HPLC-UV and Chemometrics

Comparison of Surface-Enhanced Raman Scattering Properties of Serum and Urine for the Detection of Chronic Kidney Disease in Patients

Determination Of 17 Alpha-Estradiol And 17 Beta-Estradiol In Urine By High Performance Liquid Chromatography With Pre-Column Derivatization

Analysis of Cyclosporine A and Its Metabolites in Rat Urine and Feces by Liquid Chromatography–tandem Mass Spectrometry

The analytical approach for detection of carbamylated erythropoietin for doping control purposes

Comparison of analytical approaches for the detection of oral testosterone undecanoate administration in men